Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA-guided adjuvant chemotherapy for stage II colon cancer
NL-OMON25151Not yet recruiting
- Sponsor
- Dutch Colorectal Cancer Group
- Start
- Jan 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of capecitabine, oxaliplatin, fluorouracil and folinic acid in colon cancer (2 arms), sponsored by Dutch Colorectal Cancer Group. Primary endpoint: 2-year recurrence rate. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
capecitabineoxaliplatinfluorouracilfolinic acid
03
Conditions
colon cancer
Beyond the preview
Go deeper on NL-OMON25151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25151.